Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.

Jewelry shops are seeing an increase in business due to the popularity of weight loss drugs. Women using drugs, like Ozempic, are heading to jewelers in droves to size down their rings. Van Guilder’s ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), The Home ...

Receding floodwaters that submerged homes days before left the residents of Mthatha, South Africa, helpless. They watched the bodies of their families and ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...